209 related articles for article (PubMed ID: 31308344)
1. [The analysis of Th2 cell subsets in house dust mite allergic rhinitis patients after sublingual immunotherapy].
Ihara F; Sakurai D; Okamoto Y
Nihon Yakurigaku Zasshi; 2019; 154(1):12-16. PubMed ID: 31308344
[TBL] [Abstract][Full Text] [Related]
2. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy.
Ihara F; Sakurai D; Yonekura S; Iinuma T; Yagi R; Sakurai T; Ito T; Matsuura A; Morimoto Y; Arai T; Suzuki S; Katayama K; Nakayama T; Okamoto Y
Allergy; 2018 Sep; 73(9):1823-1832. PubMed ID: 29517806
[TBL] [Abstract][Full Text] [Related]
3. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis.
Meng Q; Liu X; Li P; He L; Xie J; Gao X; Wu X; Su F; Liang Y
Int Forum Allergy Rhinol; 2016 Aug; 6(8):862-70. PubMed ID: 27012942
[TBL] [Abstract][Full Text] [Related]
4. House dust mite sublingual immunotherapy in allergic rhinitis.
Cho SW; Han DH; Kim JW; Kim DY; Rhee CS
Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
7. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
8. Decreased level of osteopontin in children with allergic rhinitis during sublingual immunotherapy.
Wang C; Wang K; Liu S; Qin X; Chen K; Zhang T
Int J Pediatr Otorhinolaryngol; 2016 Feb; 81():15-20. PubMed ID: 26810282
[TBL] [Abstract][Full Text] [Related]
9. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
[TBL] [Abstract][Full Text] [Related]
10. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
11. Role of BAFF in pediatric patients with allergic rhinitis during sublingual immunotherapy.
Luo R; Liu W; Wang J; Chen Y; Sun C; Zhou L; Li Y; Deng L
Eur J Pediatr; 2014 Aug; 173(8):1033-40. PubMed ID: 24585100
[TBL] [Abstract][Full Text] [Related]
12. Clinical and cytokine responses to house dust mite sublingual immunotherapy.
Potter PC; Baker S; Fenemore B; Nurse B
Ann Allergy Asthma Immunol; 2015 Apr; 114(4):327-34. PubMed ID: 25661658
[TBL] [Abstract][Full Text] [Related]
13. Increase in the prevalence of follicular regulatory T cells correlates with clinical efficacy of sublingual immunotherapy with house dust mites.
Murao T; Kouzaki H; Arai H; Matsumoto K; Nakamura K; Kawakita K; Tojima I; Shimizu S; Yuta A; Shimizu T
Int Forum Allergy Rhinol; 2024 Jan; 14(1):57-67. PubMed ID: 37345377
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
Demoly P; Kleine-Tebbe J; Rehm D
Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339
[TBL] [Abstract][Full Text] [Related]
15. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
[TBL] [Abstract][Full Text] [Related]
16. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
Meteran H; Backer V
Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
[No Abstract] [Full Text] [Related]
17. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.
Wang ZX; Shi H
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
[TBL] [Abstract][Full Text] [Related]
19. Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients.
Zhu K; Xia C; Chen J; Yu C; Gao T; Yan J; Shao N; Zhu P; Sun B; Ren X; Zhang Y
Mediators Inflamm; 2021; 2021():5576596. PubMed ID: 34194284
[TBL] [Abstract][Full Text] [Related]
20. Serum Periostin as a Biomarker for Predicting Clinical Response to House Dust Mite Sublingual Immunotherapy in Allergic Rhinitis.
Hoshino M; Akitsu K; Kubota K; Ohtawa J
J Allergy Clin Immunol Pract; 2021 May; 9(5):1864-1870. PubMed ID: 33290915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
